Testing Trimodulin for severe pneumonia on breathing support
Part of Infections, Lungs & breathing clinical trials.
This trial tests an investigational medicine called Trimodulin (BT588) for people with severe pneumonia who need a breathing machine. The goal is to see if it helps them recover faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are in the hospital with severe pneumonia that started outside the hospital (community-acquired).
- You are on a breathing machine (invasive mechanical ventilation) because of your pneumonia.
- You are at least 18 years old (or 12 in the US).
- You do not have severe kidney, liver, or heart disease that was present before this pneumonia.
- You have not been in another research study or received certain medications in the past few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SR1375 for adults with severe community-acquired pneumonia (a lung infection) who are not improving with standard antibiotics. It may help reduce inflammation and speed up recovery.
This trial tests two noninvasive breathing support methods (NIV and HVNI) for people with pneumonia who are having trouble breathing. The goal is to see which method works better to help you avoid needing a breathing tube.
This Phase 3 trial tests whether an anti-clot “blood thinner” can reduce complications from community-acquired pneumonia in hospitalized adults who need extra oxygen. It may help by lowering harmful clot-related effects during serious lung infection.
This study tests ways to improve treatment for adults with severe pneumonia that lands them in the ICU, adjusting the plan as results come in. It may help your care team find better treatments for lung infection and breathing/heart support needs.
This trial tests different treatment strategies for severe pneumonia in patients who are in the ICU, on a breathing machine, and sedated. The goal is to find the best approach to help you recover.
This trial tests a drug called Polymyxin E2 Methanesulfonate for a serious lung infection that patients can get in the hospital, caused by bacteria that don't respond to common antibiotics. It may be an option for people on ventilators or recently hospitalized with pneumonia that standard drugs can't treat.
Hear when a new Community-acquired Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.